Siegel RL, Miller KD. Jemal A (2019) Cancer statistics. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.

Article  PubMed  Google Scholar 

Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D’Angelica MI, Endo I, Parks RW, Doyle M, de Santibanes E, Pawlik TM. Liver metastases Nat Rev Dis Primers. 2021;7(1):27. https://doi.org/10.1038/s41572-021-00261-6.

Article  PubMed  Google Scholar 

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T, Group EG-ITC, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft O, Australasian Gastro-Intestinal Trials G, Federation Francophone de Cancerologie D (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial Lancet Oncol 14 (12):1208-1215. https://doi.org/10.1016/S1470-2045(13)70447-9

Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014;15(11):1245–53. https://doi.org/10.1016/S1470-2045(14)70377-8.

Article  CAS  PubMed  Google Scholar 

Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9. https://doi.org/10.1200/JCO.2007.14.9930.

Article  CAS  PubMed  Google Scholar 

Gruenberger T, Bridgewater J, Chau I, Garcia Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26(4):702–8. https://doi.org/10.1093/annonc/mdu580.

Article  CAS  PubMed  Google Scholar 

Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A, Investigators GF. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(4):497–507. https://doi.org/10.1016/S1470-2045(19)30862-9.

Article  CAS  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

Article  CAS  PubMed  Google Scholar 

Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Kaur H, Charnsangavej C, Loyer EM. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302(21):2338–44. https://doi.org/10.1001/jama.2009.1755.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mazard T, Boonsirikamchai P, Overman MJ, Asran MA, Choi H, Herron D, Eng C, Maru DM, Ychou M, Vauthey JN, Loyer EM, Kopetz S. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut. 2018;67(6):1095–102. https://doi.org/10.1136/gutjnl-2017-313786.

Article  CAS  PubMed  Google Scholar 

Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J, Bouche O, Francois E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Ben Abdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F, Texereau P, Suc E, Lepage C, Aparicio T, Hoeffel C, Investigators P, Investigators P. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Gut. 2020;69(3):531–9. https://doi.org/10.1136/gutjnl-2018-316407.

Article  CAS  PubMed  Google Scholar 

Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012;30(36):4566–72. https://doi.org/10.1200/JCO.2012.45.2854.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshita H, Hosokawa A, Ueda A, Ando T, Kajiura S, Kato H, Kawabe H, Tomizawa G, Horikawa N, Yabuhita K, Note M, Sugiyama T. Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases. Digestion. 2014;89(1):43–8. https://doi.org/10.1159/000356218.

Article  CAS  PubMed  Google Scholar 

Latacz E, van Dam PJ, Vanhove C, Llado L, Descamps B, Ruiz N, Joye I, Grunhagen D, Van Laere S, Dirix P, Mollevi DG, Verhoef C, Dirix L, Vermeulen P. Can medical imaging identify the histopathological growth patterns of liver metastases? Semin Cancer Biol. 2021;71:33–41. https://doi.org/10.1016/j.semcancer.2020.07.002.

Article  PubMed  Google Scholar 

Vriens D, van Laarhoven HW, van Asten JJ, Krabbe PF, Visser EP, Heerschap A, Punt CJ, de Geus-Oei LF, Oyen WJ. Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate. J Nucl Med. 2009;50(11):1777–84. https://doi.org/10.2967/jnumed.109.064790.

Article  CAS  PubMed  Google Scholar 

De Bruyne S, Van Damme N, Smeets P, Ferdinande L, Ceelen W, Mertens J, Van de Wiele C, Troisi R, Libbrecht L, Laurent S, Geboes K, Peeters M. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer. 2012;106(12):1926–33. https://doi.org/10.1038/bjc.2012.184.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu LH, Zhou GF, Lv H, Wang ZC, Rao SX, Zeng MS. Identifying response in colorectal liver metastases treated with bevacizumab: development of RECIST by combining contrast-enhanced and diffusion-weighted MRI. Eur Radiol. 2021;31(8):5640–9. https://doi.org/10.1007/s00330-020-07647-2.

Article  CAS  PubMed  Google Scholar 

Boraschi P, Donati F, Cervelli R, Pacciardi F, Tarantini G, Castagna M, Urbani L, Lencioni R. Colorectal liver metastases: ADC as an imaging biomarker of tumor behavior and therapeutic response. Eur J Radiol. 2021;137:109609. https://doi.org/10.1016/j.ejrad.2021.109609.

Article  PubMed  Google Scholar 

Majeed NF, BraschiAmirfarzan M, Wald C, Wortman JR. Spectral detector CT applications in advanced liver imaging. Br J Radiol. 2021;94(1123):20201290. https://doi.org/10.1259/bjr.20201290.

Article  PubMed  PubMed Central  Google Scholar 

Hellbach K, Sterzik A, Sommer W, Karpitschka M, Hummel N, Casuscelli J, Ingrisch M, Schlemmer M, Graser A, Staehler M. Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer. Eur Radiol. 2017;27(6):2532–7. https://doi.org/10.1007/s00330-016-4597-7.

Article  CAS  PubMed  Google Scholar 

Wang X, Liu D, Zeng X, Jiang S, Li L, Yu T, Zhang J. Dual-energy CT quantitative parameters for evaluating Immunohistochemical biomarkers of invasive breast cancer. Cancer Imaging. 2021;21(1):4. https://doi.org/10.1186/s40644-020-00370-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luo N, Li W, Xie J, Fu D, Liu L, Huang X, Su D, Jin G. Preoperative normalized iodine concentration derived from spectral CT is correlated with early recurrence of hepatocellular carcinoma after curative resection. Eur Radiol. 2021;31(4):1872–82. https://doi.org/10.1007/s00330-020-07330-6.

Article  CAS  PubMed  Google Scholar 

Shi HY, Lu ZP, Li MN, Ge YQ, Jiang KR, Xu Q. Dual-Energy CT Iodine Concentration to Evaluate Postoperative Pancreatic Fistula after Pancreatoduodenectomy. Radiology. 2022;304(1):65–72. https://doi.org/10.1148/radiol.212173.

Article  PubMed  Google Scholar 

Sakai N, Furukawa K, Takayashiki T, Kuboki S, Takano S, Ohtsuka M. Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases. BMC Cancer. 2021;21(1):412. https://doi.org/10.1186/s12885-021-08144-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tosi F, Magni E, Amatu A, Mauri G, Bencardino K, Truini M, Veronese S, De Carlis L, Ferrari G, Nichelatti M, Sartore-Bianchi A, Siena S. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. Clin Colorectal Cancer. 2017;16(3):e153–63. https://doi.org/10.1016/j.clcc.2017.01.004.

Article  PubMed  Google Scholar 

Zimmitti G, Shindoh J, Mise Y, Kopetz S, Loyer EM, Andreou A, Cooper AB, Kaur H, Aloia TA, Maru DM, Vauthey JN. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol. 2015;22(3):834–42. https://doi.org/10.1245/s10434-014-4042-6.

Article  PubMed  Google Scholar 

Garcia-Carbonero N, Martinez-Useros J, Li W, Orta A, Perez N, Carames C, Hernandez T, Moreno I, Serrano G, Garcia-Foncillas J (2020) KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. Cells 9 (1). https://doi.org/10.3390/cells9010219

Margonis GA, Amini N, Andreatos N, Sasaki K, McVey J, Mirza MB, Warner S, Buettner S, Barbon C, Wang J, Pulvirenti A, Angelou A, Kamphues C, Antoniou E, Pikoulis E, Pawlik TM, Kaczirek K, Poultsides G, Wagner D, Endo I, Imai K, Aucejo F, Kreis ME, Wolfgang CL, Weiss MJ. KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases. HPB (Oxford). 2019;21(11):1527–34. https://doi.org/10.1016/j.hpb.2019.03.368.

Article  PubMed  Google Scholar 

Suzuki C, Blomqvist L, Sundin A, Jacobsson H, Bystrom P, Berglund A, Nygren P, Glimelius B. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol. 2012;23(4):948–54. https://doi.org/10.1093/annonc/mdr350.

Article  CAS  PubMed  Google Scholar 

Yang G, Wang G, Sun J, Xiong Y, Li W, Tang T, Li J. The prognosis of radiofrequency ablation versus hepatic resection for patients with colorectal liver metastases: A systematic review and meta-analysis based on 22 studies. Int J Surg. 2021;87:105896. https://doi.org/10.1016/j.ijsu.2021.105896.

Article  PubMed  Google Scholar 

Nakanishi R, Oki E, Hasuda H, Sano E, Miyashita Y, Sakai A, Koga N, Kuriyama N, Nonaka K, Fujimoto Y, Jogo T, Hokonohara K, Hu Q, Hisamatsu Y, Ando K, Kimura Y, Yoshizumi T, Mori M. Radiomics Texture Analysis for the Identification of Colorectal Liver Metastases Sensitive to First-Line Oxaliplatin-Based Chemotherapy. Ann Surg Oncol. 2021;28(6):2975–85. https://doi.org/10.1245/s10434-020-09581-5.